Avesta76 is focused on a target that has the potential to treat every type of tumor.
Market:Avesta76's therapies will address the need for safe and effective treatments across multiple cancers. This is a market with 17 million annual diagnoses, 10 million deaths, and over $150B spent on drugs per year. The company's initial focus is on ovarian cancer, a $5.9B market growing by 7% annually with over 21,000 new cases and 13,000 deaths in the U.S. each year.
Technology:Avesta76’s drug target has been thoroughly validated through preclinical research in cells and animal models, and has the potential to act as a cancer “masterswitch.” By inhibiting the target, the company’s therapies disrupt the normal function of a biochemical pathway that cancer needs in order to grow, safely spurring remission and preventing the formation of new tumors in peer-reviewed studies. Both small-molecule drugs and monoclonal antibodies are under development.
- Unique drug target
- Fundamentally disrupts necessary cancer pathways
- Effective across all cancer types
- No observed adverse effects
- Multiple drug candidates
- Coming Soon
- Rlip depletion prevents spontaneous neoplasia in TP53 null mice | PNAS
- Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis | Cancers
- Rlip Depletion Suppresses Growth of Breast Cancer | Cancers